Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130812 | 0.91 | NR1H2 (0.67) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL6499027 | 0.91 | ESR2 (0.69) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL396485 | 0.91 | NR1H2 (0.67) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL4674208 | 0.89 | NR1H2 (0.58) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL31591055 | 0.87 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL27034845 | 0.87 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL30561507 | 0.85 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL1655858 | 0.85 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL2306719 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTESR2NR1H2 | |
| SCHEMBL20704324 | 0.83 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216197-A2 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | ACELOT, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-110818724-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107253963-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-04-14 | — | — | CN | disclosed |
| CN-110818724-A | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| CN-107253963-A | Pyridone and azepine pyridinone compounds and application method | 吉利德康涅狄格有限公司 | 2017-10-17 | — | — | CN | disclosed |
| CN-103038233-B | Pyridone and azapyridone compounds and methods of use | 吉利德康涅狄格有限公司 | 2017-06-20 | — | — | CN | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050222124-A1 | Benzenesulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
| CN-1630642-A | Benzenesulfonamide derivatives | GLAXO GROUP LTD (GB) | 2005-06-22 | — | — | CN | disclosed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | disclosed |
| EP-1474399-A1 | BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003068752-A1 | BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | ALDH1A1 3206/4885LMNA 2383/4885MAPT 2025/4885 |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | ALDH1A1 4524/4885LMNA 2461/4885MAPT 4618/4885 |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | ALDH1A1 3206/4885LMNA 2383/4885MAPT 2025/4885 |
| US-20050222124-A1 | Benzenesulfonamide derivatives as antipsychotic agents | SIGMAR1, CNR1, CBR1 | ALDH1A1 1821/4885LMNA 2723/4885MAPT 3969/4885 |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | ALDH1A1 3206/4885LMNA 2383/4885MAPT 2025/4885 |
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | ALDH1A1 3358/4885LMNA 4640/4885MAPT 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.